Ando Kumiko, Ishikura Reiichi, Nagami Yuki, Morikawa Tsutomu, Takada Yoshihiro, Ikeda Jota, Nakao Norio, Matsumoto Tsuyoshi, Arita Norio
Department of Radiology, Hyogo College of Medicine.
Nihon Igaku Hoshasen Gakkai Zasshi. 2004 Mar;64(3):121-6.
We evaluated the clinical usefulness of the Cho/Cr ratio of proton MR spectroscopy(1H-MRS) to differentiate residual/recurrent glioma from non-neoplastic lesions.
20 cases of glioma were involved in this study(astrocytoma grade I-II: 7, oligodendroglioma: 1, astrocytoma grade III: 2, glioblastoma: 10). Seven of the patients underwent surgical resection only, 4 underwent surgical resection and radiotherapy(40-60 Gy), and 9 underwent surgical resection and radiotherapy with concurrent chemotherapy(14-60 Gy). 1H-MRS was performed on a 1.5 Tesla clinical MR unit using a 3D-chemical shift imaging sequence(1500 msec/270 msec/1 (TR/TE/excitations), and the Cho/Cr ratio was calculated in the voxel where neoplastic lesion was most suspected on MRI. The presence of lactate + lipid peak was also evaluated. All spectra were obtained after the contrast enhanced study.
Cho/Cr ratios were significantly higher in cases of residual/recurrent tumors(mean +/- SD = 1.70 +/- 0.96) than in non-neoplastic lesions(mean +/- SD = 1.04 +/- 1.16) (Mann-Whitney U-test p = 0.047). If a Cho/Cr ratio of more than 1.5 was used as a marker of tumor presence, its sensitivity was 64%, specificity 83%, and accuracy 70%. One false-positive case that of radiation necrosis whose spectrum showed a high Cho/Cr ratio with markedly elevated lactate + lipid peak.
The Cho/Cr ratio of 1H-MRS provides additional information to MRI in differentiating residual/recurrent gliomas from non-neoplastic lesions.